Lv61
2590 积分 2023-10-20 加入
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
22天前
已完结
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
22天前
已完结
FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data
1个月前
已完结
The enedioic acid analog 326E alleviates metabolic dysfunction-associated steatohepatitis via dual targeting at ACLY and PPARα
1个月前
已完结
Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
1个月前
已完结
Biomarkers of histological response in lanifibranor-treated patients with metabolic dysfunction-associated steatohepatitis
1个月前
已完结
Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
1个月前
已完结
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH
1个月前
已完结
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
1个月前
已完结
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
1个月前
已完结
皖公网安备34019202002308
